CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

被引：2
|
作者：
Hu, Xiaoyi [1 ]
Ediriwickrema, Asiri [1 ]
Saleem, Atif [2 ]
Tan, Brent [1 ]
Pemmaraju, Naveen [3 ]
Mannis, Gabriel N. [1 ]
机构：
[1] Stanford Univ, Canc Inst, Dept Med, Div Hematol, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
LEUKEMIA RESEARCH | 2024年 / 139卷
关键词：
BPDCN; Tagraxofusp; CD123; Daratumumab; Venetoclax;
D O I：
10.1016/j.leukres.2024.107479
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 22 条
  • [21] CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study.
    Budde, Lihua E.
    Song, Joo
    Del Real, Marissa
    Kim, Young
    Toribio, Candida
    Wood, Brent
    Wagner, Jamie
    Marcucci, Emanuela
    Stein, Anthony
    Marcucci, Guido
    Brown, Christine E.
    Forman, Stephen J.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 33 - 34
  • [22] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Daver, Naval G.
    Montesinos, Pau
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Papadantonakis, Nikolaos
    Deconinck, Eric
    Erba, Harry P.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Rizzieri, David A.
    Sweet, Kendra L.
    Martinelli, Giovanni
    Tarella, Corrado
    Todisco, Elisabetta
    Konopleva, Marina Y.
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
123